Abstract
Anti-cytokine autoantibodies (ACAAs) have been described in a growing number of primary immunodeficiencies with autoimmune features, including autoimmune polyendocrine syndrome type I (APS-1), a prototypical disease of defective T cell-mediated central tolerance. Whether defects in peripheral tolerance lead to similar ACAAs is unknown. Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) is caused by mutations in FOXP3, a master regulator of T regulatory cells (Treg), and consequently results in defective T cell-mediated peripheral tolerance. Unique autoantibodies have previously been described in IPEX. To test the hypothesis that ACAAs are present in IPEX, we designed and fabricated antigen microarrays. We discovered elevated levels of IgG ACAAs against interferon-α (IFN-α) in a cohort of IPEX patients. Serum from IPEX patients blocked IFN-α signaling in vitro and blocking activity was tightly correlated with ACAA titer. To show that blocking activity was mediated by IgG and not other serum factors, we purified IgG and showed that blocking activity was contained entirely in the immunoglobulin fraction. We also screened for ACAAs against IFN-α in a second geographically distinct cohort. In these samples, ACAAs against IFN-α were elevated in a post hoc analysis. In summary, we report the discovery of ACAAs against IFN-α in IPEX, an experiment of nature demonstrating the important role of peripheral T cell tolerance.
Highlights
Anti-cytokine autoantibodies (ACAAs) have been described in a growing number of immunodeficiencies [1, 2]
Anti-cytokine autoantibodies are prominent in APS-1, which is caused by mutations in autoimmune regulator (AIRE), a master regulator of T cell central tolerance
We hypothesized that ACAAs would be a feature of Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX), caused by mutations in FOXP3, a master regulator of T regulatory cells (Treg), as IPEX patients have defects in peripheral T cell tolerance
Summary
Anti-cytokine autoantibodies (ACAAs) have been described in a growing number of immunodeficiencies [1, 2]. ACAAs have been identified in the serum of patients with autoimmune disease and healthy donors [3,4,5,6]. The prevalence of ACAAs in many human diseases, and their contributions to phenotype, remain understudied. High titer ACAAs against IFN-α and other type I IFNs are strikingly specific to the disease autoimmune polyendocrine syndrome type I (APS-1), they have been described in the following rare conditions with varying penetrance: patients with thymoma, patients with hypomorphic RAG1 or RAG2 mutations, and in a patient with an NFKB2 mutation [8,9,10]. We will refer to the tested protein, IFN-α A, as IFN-α
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.